Oligonucleotides comprising a non-phosphate backbone linkage
    51.
    发明授权
    Oligonucleotides comprising a non-phosphate backbone linkage 有权
    包含非磷酸骨架键的寡核苷酸

    公开(公告)号:US07615618B2

    公开(公告)日:2009-11-10

    申请号:US11170798

    申请日:2005-06-29

    IPC分类号: C07H19/00 C07H21/00

    摘要: One aspect of the present invention relates to a ribonucleoside substituted with a phosphonamidite group at the 3′-position. In certain embodiments, the phosphonamidite is an alkyl phosphonamidite. Another aspect of the present invention relates to a double-stranded oligonucleotide comprising at least one non-phosphate linkage. Representative non-phosphate linkages include phosphonate, hydroxylamine, hydroxylhydrazinyl, amide, and carbamate linkages. In certain embodiments, the non-phosphate linkage is a phosphonate linkage. In certain embodiments, a non-phosphate linkage occurs in only one strand. In certain embodiments, a non-phosphate linkage occurs in both strands. In certain embodiments, a ligand is bound to one of the oligonucleotide strands comprising the double-stranded oligonucleotide. In certain embodiments, a ligand is bound to both of the oligonucleotide strands comprising the double-stranded oligonucleotide. In certain embodiments, the oligonucleotide strands comprise at least one modified sugar moiety. Another aspect of the present invention relates to a single-stranded oligonucleotide comprising at least one non-phosphate linkage. Representative non-phosphate linkages include phosphonate, hydroxylamine, hydroxylhydrazinyl, amide, and carbamate linkages. In certain embodiments, the non-phosphate linkage is a phosphonate linkage. In certain embodiments, a ligand is bound to the oligonucleotide strand. In certain embodiments, the oligonucleotide comprises at least one modified sugar moiety.

    摘要翻译: 本发明的一个方面涉及在3'-位被亚磷酰胺基取代的核糖核苷。 在某些实施方案中,亚磷酰胺是烷基亚磷酰胺。 本发明的另一方面涉及包含至少一种非磷酸键的双链寡核苷酸。 代表性的非磷酸酯键包括膦酸酯,羟胺,羟基肼基,酰胺和氨基甲酸酯键。 在某些实施方案中,非磷酸酯键是膦酸酯键。 在某些实施方案中,非磷酸酯键仅出现在一条链中。 在某些实施方案中,在两条链中都发生非磷酸连接。 在某些实施方案中,配体与包含双链寡核苷酸的寡核苷酸链之一结合。 在某些实施方案中,配体与包含双链寡核苷酸的两条寡核苷酸链结合。 在某些实施方案中,寡核苷酸链包含至少一个修饰的糖部分。 本发明的另一方面涉及包含至少一种非磷酸键的单链寡核苷酸。 代表性的非磷酸酯键包括膦酸酯,羟胺,羟基肼基,酰胺和氨基甲酸酯键。 在某些实施方案中,非磷酸酯键是膦酸酯键。 在某些实施方案中,配体与寡核苷酸链结合。 在某些实施方案中,寡核苷酸包含至少一个修饰的糖部分。

    Carbohydrate Conjugates as Delivery Agents for Oligonucleotides
    52.
    发明申请
    Carbohydrate Conjugates as Delivery Agents for Oligonucleotides 有权
    碳水化合物缀合物作为寡核苷酸的递送剂

    公开(公告)号:US20090239814A1

    公开(公告)日:2009-09-24

    申请号:US12328528

    申请日:2008-12-04

    IPC分类号: A61K31/715 C07H17/02 C12N5/06

    摘要: The present invention provides iRNA agents comprising at least one subunit of the formula (I): wherein: A and B are each independently for each occurrence O, N(RN) or S; X and Y are each independently for each occurrence H, OH, a hydroxyl protecting group, a phosphate group, a phosphodiester group, an activated phosphate group, an activated phosphite group, a phosphoramidite, a solid support, —P(Z′)(Z″)O-nucleoside, —P(Z′)(Z″)O-oligonucleotide, a lipid, a PEG, a steroid, a lipophile, a polymer, —P(Z′)(Z″)O-Linker-OP(Z′″)(Z″″)O-oligonucleotide, a nucleotide, an oligonucleotide, —P(Z′)(Z″)-formula (I), —P(Z′)(Z″)— or -Linker-R; R is LG, -Linker-LG, or has the structure shown below: LG is independently for each occurrence a carbohydrate, e.g., monosaccharide, disaccharide, trisaccharide, tetrasaccharide, oligosaccharide, polysaccharide; RN is independently for each occurrence H, methyl, ethyl, propyl, isopropyl, butyl, or benzyl; and Z′, Z″, Z′″ and Z″″ are each independently for each occurrence O or S.

    摘要翻译: 本发明提供包含至少一个式(I)亚基的iRNA试剂:其中:A和B各自独立地为O,N(RN)或S; X和Y各自独立地为H,OH,羟基保护基,磷酸基,磷酸二酯基,活化磷酸酯基,活化亚磷酸酯基,亚磷酰胺,固体载体,-P(Z')( Z')(Z“)O - 寡核苷酸,脂质,PEG,类固醇,亲脂体,聚合物,-P(Z')(Z”)O (Z')(Z“) - (Z”)(Z“)(Z”)(Z“)(Z”) (Z“) - 或-Linker-R; R是LG,-Linker-LG,或具有如下结构:每次出现LG独立为碳水化合物,例如单糖,二糖,三糖,四糖,寡糖,多糖; 乙烯基,丙基,异丙基,丁基或苄基各自独立地为N, Z',Z“,Z”“和Z”“各自独立地为O或S.

    5′ phosphate mimics
    55.
    发明授权
    5′ phosphate mimics 有权
    5'磷酸酯类似物

    公开(公告)号:US08927513B2

    公开(公告)日:2015-01-06

    申请号:US13382346

    申请日:2010-07-07

    摘要: The present invention provides nucleosides and oligonucleotides comprising a 5′ phosphate mimics of formula (IVc) or (Vc). One aspect of the present invention relates to modified nucleosides and oligonucleotides comprising such dinucleotide of formula (Ia). Another aspect of the invention relates to a method of inhibiting the expression of a gene in call, the method comprising (a) contacting an oligonucleotide of the invention with the cell; and (b) maintaining the cell from step (a) for a time sufficient to obtain degradation of the mRNA of the target gene.

    摘要翻译: 本发明提供了包含式(IVc)或(Vc)的5'磷酸酯模拟物的核苷和寡核苷酸。 本发明的一个方面涉及包含式(Ia)的二核苷酸的修饰核苷和寡核苷酸。 本发明的另一方面涉及一种抑制基因表达的方法,所述方法包括(a)使本发明的寡核苷酸与细胞接触; 和(b)将来自步骤(a)的细胞维持足以获得靶基因的mRNA降解的时间。

    Modified iRNA agents
    60.
    发明授权
    Modified iRNA agents 有权
    修饰的iRNA试剂

    公开(公告)号:US08344125B2

    公开(公告)日:2013-01-01

    申请号:US12619382

    申请日:2009-11-16

    IPC分类号: C07H21/04 A61K31/70

    摘要: The invention relates to iRNA agents, which preferably include a monomer in which the ribose moiety has been replaced by a moiety other than ribose. The inclusion of such a monomer can allow for modulation of a property of the iRNA agent into which it is incorporated, e.g., by using the non-ribose moiety as a point to which a ligand or other entity, e.g., a carbohydrate; or a steroid, e.g., cholesterol, which is optionally substituted with at least one carbohydrate. is directly, or indirectly, tethered. The invention also relates to methods of making and using such modified iRNA agents.

    摘要翻译: 本发明涉及iRNA试剂,其优选包括其中核糖部分被除核糖以外的部分替代的单体。 包含这样的单体可以允许调节其引入其中的iRNA试剂的性质,例如通过使用非核糖部分作为配体或其他实体例如碳水化合物的点; 或类固醇,例如胆固醇,其任选被至少一种碳水化合物取代。 是直接或间接地束缚着。 本发明还涉及制备和使用这种修饰的iRNA试剂的方法。